This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Gandotinib
DrugBank Accession Number
DB13040
Background

Gandotinib has been used in trials studying the treatment of Myelofibrosis, Polycythemia Vera, Primary Myelofibrosis, Thrombocythemia, Essential, and Myeloproliferative Disorders, among others.

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 469.95
Monoisotopic: 469.1793143
Chemical Formula
C23H25ClFN7O
Synonyms
  • Gandotinib
External IDs
  • LY-2784544
  • LY2784544

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as aminopyridazines. These are organic compounds containing an amino group attached to a pyridazine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazines
Sub Class
Pyridazines and derivatives
Direct Parent
Aminopyridazines
Alternative Parents
Aralkylamines / Fluorobenzenes / Chlorobenzenes / Aryl chlorides / N-substituted imidazoles / Morpholines / Imidolactams / Aryl fluorides / Pyrazoles / Heteroaromatic compounds
show 7 more
Substituents
Amine / Aminopyridazine / Aralkylamine / Aromatic heteropolycyclic compound / Aryl chloride / Aryl fluoride / Aryl halide / Azacycle / Azole / Benzenoid
show 24 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
ANC71R916O
CAS number
1229236-86-5
InChI Key
SQSZANZGUXWJEA-UHFFFAOYSA-N
InChI
InChI=1S/C23H25ClFN7O/c1-14-9-21(29-28-14)27-22-11-17(13-31-5-7-33-8-6-31)23-26-15(2)20(32(23)30-22)10-16-3-4-18(24)12-19(16)25/h3-4,9,11-12H,5-8,10,13H2,1-2H3,(H2,27,28,29,30)
IUPAC Name
N-{3-[(4-chloro-2-fluorophenyl)methyl]-2-methyl-8-[(morpholin-4-yl)methyl]imidazo[1,2-b]pyridazin-6-yl}-5-methyl-1H-pyrazol-3-amine
SMILES
CC1=CC(NC2=NN3C(CC4=CC=C(Cl)C=C4F)=C(C)N=C3C(CN3CCOCC3)=C2)=NN1

References

General References
Not Available
PubChem Compound
46213929
PubChem Substance
347829172
ChemSpider
25027412
ChEMBL
CHEMBL2107823
ZINC
ZINC000068245097
Wikipedia
Gandotinib

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Active Not RecruitingTreatmentNeoplasms, Hematologic1
1CompletedTreatmentEssential Thrombocythemia (ET) / Myelofibrosis / Myeloproliferative Neoplasms of / Polycythemia Vera (PV)1
1CompletedTreatmentEssential Thrombocythemia (ET) / Myeloproliferative Disorders (MPD) / Polycythemia Vera (PV) / Primary Myelofibrosis (PMF)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0144 mg/mLALOGPS
logP4.05ALOGPS
logP4.24ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)12.56ChemAxon
pKa (Strongest Basic)5.74ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area83.37 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity138.72 m3·mol-1ChemAxon
Polarizability49.21 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at October 21, 2016 02:19 / Updated at February 21, 2021 18:54